Geldanamycin

As one of the lead compounds that entered clinical research the earliest in the field of Hsp90 inhibitors, geldanamycin belongs to the benzoquinone ansamycin antibiotics. It specifically binds to the N-terminal ATP-binding domain of heat shock protein 90 (Hsp90), blocks its molecular chaperone function, and then induces the degradation of a variety of tumor-related client proteins, thus exerting anti-tumor activity. Early studies have shown that it has potential therapeutic effects on a variety of solid tumors and hematological malignancies. Meanwhile, the R&D of its derivatives has also been expanded to indications such as antiviral and anti-fibrosis fields, making it an important research tool for the development of anti-tumor targeted drugs.

Limited by the high toxicity and insufficient druggability of natural products, geldanamycin is currently mainly supplied in the form of API for drug R&D and derivative development links. The global market size of related R&D reagents and customized synthesis is approximately USD 120 million, with a compound annual growth rate of 8.7% in the past three years. The core demand is concentrated in laboratories of scientific research institutions and the early R&D pipelines of innovative pharmaceutical companies. Currently, the market supply is dominated by high-end scientific research reagent manufacturers, and it has not yet entered the large-scale production supporting stage of commercialized drugs.

Geldanamycin was originally isolated from the culture broth of Streptomyces by Merck & Co., Inc. in the United States. It has no commercialized original research trade name, and its basic compound patent has expired worldwide. At present, there is no approved and marketed original research preparation of geldanamycin. There is no approved geldanamycin preparation variety in China, and there is no valid geldanamycin API registration number on the CDE API registration platform. It is only circulated in the form of scientific research chemicals and reference standards. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO provides a full set of impurity reference standards for geldanamycin, covering the needs of the whole process of targeted synthesis, impurity qualitative and quantitative analysis, and quality research in the R&D process. Most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. They comply with the regulatory requirements of the Chinese Pharmacopoeia and FDA, and can stably support the needs of related R&D and quality control scenarios.